A recent study reveals that patients who come off new GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight far faster than those who end conventional lifestyle plans.
Published data in a major health publication shows that while obese individuals can lose about a fifth of their total mass while undergoing treatment, the weight returns at an average rate of 0.8 kg per month after stopping.
"People purchasing these drugs must be aware of the potential of quick weight regain when the treatment concludes," warns expert Dr. Susan Jebb.
This pace of regain means a reversion to pre-treatment mass in about 18 months.
Analyzing Approaches
The research, which reviewed 37 of studies involving over 9,000 of patients, compared the effects of the injectable medications with other pills.
The team emphasize that individuals who lose weight through lifestyle changes alone usually see a slower weight regain—approximately 0.1 kg a month—post-intervention.
Explaining the Quick Rebound
Nutrition scientists suggest the way of the jabs accounts for the heightened weight return.
GLP-1 drugs mimic a body's own chemical called GLP-1, which controls hunger.
"Sustained high doses of GLP-1 concentrations several times higher than normal might result in the system to produce less of its endogenous hormone, and may also reduce sensitivity to its actions," noted Dr. Adam Collins, a nutrition specialist.
"Stopping of this hormone supplement results in hunger is unsuppressed, making binge eating much more probable."
A Lifelong Disease?
Health authorities advise the injections for individuals with obesity-related health risks, alongside prescribed diet and exercise modifications.
A number of clinicians contend that, given the high risk of relapse, the treatment should be considered ongoing.
This perspective is echoed by pharmaceutical companies, who say that the results "highlight the persistent nature of obesity," similar to managing conditions like high blood pressure.
Patient Testimonies
Users who have discontinued the medication describe a sudden resurgence of hunger.
"It was like a switch activating and you're instantly ravenous," recalled one woman.
This difficulty is compounded if patients have not established sustainable lifestyle or habit modifications during treatment.
Widespread Use
Survey data indicate that a significant number of adults in the UK have used these injections in the past year, with demand remaining high.
- Adoption is higher among women compared to males.
- The middle-aged demographic shows the greatest usage rates.
- Many access the medications through private prescriptions rather than the NHS.
Ultimately, experts caution that while these medications are effective tools for shedding pounds, they are not a magic solution and lasting health benefits hinges on ongoing lifestyle management.
